Response to rituximab in children and adults with immune thrombocytopenia (ITP)
Abstract Background Rituximab is a monoclonal anti‐CD20 antibody used as a second‐line treatment for immune thrombocytopenia (ITP). As additional treatments for ITP emerge, identifying the most appropriate patients and optimal timing for rituximab are important but challenging without established pr...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2021-08-01
|
| coleção: | Research and Practice in Thrombosis and Haemostasis |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1002/rth2.12587 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|